High level synthesis of recombinant soluble urokinase receptor (CD87) by ovarian cancer cells reduces intraperitoneal tumor growth and spread in nude mice

Biological Chemistry

Volumn 382, Issue 5, 2001, Pages 789-798

  Lutz, V ^a   Reuning, U ^a   Kruger A ^a   Luther, T ^a   von Steinburg, S P ^a   Graeff, H ^a   Schmitt, M ^a   Wilhelm, O G ^a   Magdolen, V ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

CD87; Matrix degradation; Ovarian cancer; Soluble uPAR

Indexed keywords

GLYCAN; LIPID; RECOMBINANT RECEPTOR; SCAVENGER; SERINE PROTEINASE; UROKINASE; UROKINASE RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INVASION; CANCER LOCALIZATION; CELL CLONE; CELL PROLIFERATION; CELL SURFACE; CONTROLLED STUDY; DEGRADATION; EXTRACELLULAR MATRIX; FEMALE; FIBRINOLYSIS; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INOCULATION; METASTASIS; MOUSE; NONHUMAN; NUDE MOUSE; OVARY CANCER; PERITONEUM; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; RECEPTOR BINDING; SOLUBILITY; XENOGRAFT;

ANIMALS; CELL DIVISION; FEMALE; FIBRINOLYSIS; HUMANS; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; PHENOTYPE; PLASMINOGEN; RECEPTORS, CELL SURFACE; RECOMBINANT PROTEINS; SOLUBILITY; TRANSFECTION; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0034930530     PISSN: 14316730     EISSN: None     Source Type: Journal    
DOI: 10.1515/BC.2001.095     Document Type: Article

References (48)

1. Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling
2. The urokinase-type plasminogen activator system in cancer metastasis: A review
3. The urokinase receptor. A cell surface, regulated chemokine
4. The urokinase plasminogen activator receptor in blood from healthy individuals and patients with cancer
5. Inhibition of the interaction of urokinase-type plasminogen activator (uPA) with its receptor (uPAR) by synthetic peptides
6. Urokinase receptor-dependent upregulation of smooth muscle cell adhesion to vitronectin by urokinase
7. Flow cytofluorometric analysis of the urokinase receptor (uPAR) on tumor cells by fluorescent uPA-ligand or monoclonal antibody #3936
8. Prevention of metastasis by inhibition of the urokinase receptor
9. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release?
10. Urokinase activates the Jak/Stat signal transduction pathway in human vascular endothelial cells
11. Proteolytic release of membrane proteins: Studies on a membrane-protein-solubilizing, activity in CHO cells
12. Urokinase induces proliferation of human ovarian cancer cells: Characterization of structural elements required for growth factor function
13. Function of the urokinase receptor (CD87) in neutrophil chemotaxis
14. Demonstration of urokinase expression in cancer cells of colon adenocarcinomas by immunohistochemistry and in situ hybridization
15. Urokinase receptor localization in breast cancer and benign lesions assessed by in situ hybridization and immunohistochemistry
16. The urokinase receptor is a major vitronectin-binding protein on endothelial cells
17. Overexpression of urokinase receptor increases matrix invasion without altering cell migration in a human osteosarcoma cell line
18. A bifunctional hybrid molecule of the amino-terminal fragment of urokinase and domain II of bikunin efficiently inhibits tumor cell invasion and metastasis
19. Role and localization of urokinase receptor in the formation of new microvascular structures in fibrin matrices
20. Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinase-type plasminogen activator receptor (CD87)
21. Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc
22. Adenovirus-mediated delivery of a uPA/uPAR antagonist suppresses angiogenesis-dependent tumor growth and dissemination in mice
23. Clinical relevance of the urokinase plasminogen activator system in breast cancer
24. Epitope-mapped monoclonal antibodies as tools for functional and morphological analyses of the human urokinase receptor in tumor tissue
25. Expression of the human urokinase-type plasminogen activator receptor in E. coli and Chinese hamster ovary cells: Purification of the recombinant proteins and generation of polyclonal antibodies in chicken
26. Systematic mutational analysis of the receptor-binding region of the human urokinase-type plasminogen activator
27. Immunological and functional analyses of the extracellular domain of human tissue factor
28. Adenovirus-mediated delivery of antisense gene to urokinase-type plasminogen activator receptor suppresses glioma invasion and tumor growth
29. Antibodies to plasminogen activator inhibit human tumor metastasis
30. A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer
31. Prevention of prostate cancer metastasis in vivo by a novel synthetic inhibitor of urokinase-type plasminogen activator (uPA)
32. Induction in human osteoblastic cells (SaOS2) of the early response genes fos, jun, and myc by the amino terminal fragment (ATF) of urokinase
33. Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect
34. Inhibition of NF-κB-Rel A expression by antisense-oligonucleotide suppresses synthesis of urokinase-type plasminogen activator (uPA) but not its inhibitor PAI-1
35. Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis
36. Primary tumor and metastasis in ovarian cancer differ in their content of urokinase-type plasminogen activator, its receptor, and inhibitors types 1 and 2
37. Clinical impact of the plasminogen activation system in tumor invasion and metastasis: Prognostic relevance and target for therapy
38. The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer
39. Identification and characterization of the murine cell surface receptor for the urokinase-type plasminogen activator
40. Plasma urokinase receptor levels in patients with colorectal cancer: Relationship to prognosis
41. Urokinase receptor antagonists: Discovery and application to in vivo models of tumor growth
42. Mutational analysis of the genes encoding urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) in advanced ovarian cancer
43. Soluble receptor for plasminogen activator in both full-length and a cleaved form is present in high concentration in cystic fluid from ovarian cancer
44. Regulation of integrin function by the urokinase receptor
45. Cellular glycosylphosphatidylinositol-specific phospholipase D regulates urokinase receptor shedding and cell surface expression
46. Antisense inhibition of urokinase reduces spread of human ovarian cancer in mice
47. Recombinant soluble urokinase receptor as a scavenger for urokinase-type plasminogen activator (uPA). Inhibition of proliferation and invasion of ovarian cancer cells
48. Overexpression of urokinase receptor in breast cancer cells results in increased tumor invasion, growth and metastasis